AS X-listed AtCor Medical
has announced a new contract
to supply its SphygmoCor
systems and clinical trial support
services to a “major international
pharmaceutical company”.
The SphygmoCor product noninvasively
measures central aortic
blood pressures and arterial
stiffness, with the US$600,000
contract using the system to assess
a new disease state.
CEO Duncan Ross said he was
pleased at the new contract,
with one of AtCor’s goals being
“to expand both the number of
companies using SphygmoCor and
the range of therapeutic disease
areas that employ central aortic
blood pressure measurement”The above article was sent to subscribers in Pharmacy Daily's issue from 29 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Oct 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.